Indices dipped after Johnson & Johnson (JNJ.US) release results of coronavirus vaccine trials. The company said that its one-shot vaccine is 66% effective overall in moderate to severe cases, according to findings of the global clinical trial. Shots were generally well tolerated among trial participants. This is a slightly disappointing result given that some available vaccines have prevented virus infections in over 90% of cases. However, the vaccine is said to be 85% effective in preventing severe cases. Company plans to file for the emergency use approval in the United States in early February.
DE30 dropped around 1% following lacklustre results of Johnson&Johnson coronavirus vaccine trials. Source: xStation5
Daily Summary - Powerful NFP report could delay Fed rate cuts
US OPEN: Blowout Payrolls Signal Slower Path for Rate Cuts?
BREAKING: US100 jumps amid stronger than expected US NFP report
Market wrap: Oil gains amid US - Iran tensions ๐ European indices muted before US NFP report